Merck KGaA announced leadership changes on the board of E. Merck. The company, which is legally structured as a general partnership, represents the Merck family interests in the pharmaceutical and chemicals group, Merck KgaA.
Hans Joachim Langmann, chairman of the executive board of E. Merck for 32 years, retired from this position on June 22, 2002, but will remain a member of the executive board. He also continues to act as chairman of the Merck family council, a part of E. Merck that participates in fundamental business decisions.
Jon Baumhauer has been appointed chairman of the executive board of E. Merck and Frank Stangenberg-Haverkamp vice chairman. The CEO and chairman of the executive board of Merck KGaA, Bernhard Scheuble, as well as the chief financial officer of Merck KGaA, Michael Becker, will remain members of the executive board of E. Merck.
Thomas Schreckenbach, Jan Sombroek and Michael Römer have resigned from the board of E. Merck.
“These succession measures within the Merck family highlight our majority shareholder’s clear commitment to the continuity and long-term perspective of the company,” said Prof. Scheuble. “Likewise, in spite of the on-going consolidation in the pharmaceutical and chemicals industries, Merck is determined to remain an independent company and to grow and secure its future through the strength of its own innovative products and services.”